Zevra Therapeutics, Inc. has announced the departure of its Chief Financial Officer and Treasurer, R. Laduane Clifton, effective December 31, 2025. Neil F. McFarlane, the company's CEO and President, acknowledged Clifton's significant contribution to the company since joining in 2015. The departing CFO is credited with providing steady leadership and invaluable guidance during the company's transition from a development stage into a commercial-stage entity focused on rare diseases. Clifton expressed confidence in the strong financial foundation he leaves behind as he pursues new professional opportunities.
Zevra Therapeutics, Inc. is now in the process of identifying its next Chief Financial Officer. The company, a commercial-stage entity with a mission to address unmet needs for the treatment of rare diseases, is known for its unique, data-driven development and commercialization strategies that are aimed at making new therapies available to the rare disease community.
As of the announcement date, the specific financial metrics and changes since the last reporting period were not provided. Today the company's shares have moved -6.51% to a price of $9.05. Check out the company's full 8-K submission here.
